Burak Gurses, MD
Pulmonary Disease · Mequon, WINPI 1649231754
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 91.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $7,530 and has fallen 97.9% since, to $155 in 2025.
Across 44 payments — averaging $241.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- Pulmonx Corporation$425
- AstraZeneca$142
- Galvanize Therapeutics, Inc$78
- Olympus America Inc.$59
- Covidien LP$50
- plus $136 from 5 others
What the payments were for
- Travel & lodging$3,26131%
- Food & beverage$1,36413%
- Education$6,01557%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 28 | $9,750 |
| Pulmonx Corporation | 4 | $425 |
| AstraZeneca | 2 | $142 |
| Galvanize Therapeutics, Inc | 1 | $78 |
| Olympus America Inc. | 1 | $59 |
| Covidien LP | 1 | $50 |
| Boehringer Ingelheim | 3 | $50 |
| Harmony Biosciences LLC | 1 | $26 |
| Electromed, Inc. | 1 | $23 |
| GSK | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,640 in reported general payments places this provider in the 85th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 270 | $222,214 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 95 | $60,245 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $36,660 |
| Spiriva RespimatTiotropium Bromide | 33 | $31,052 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $13,745 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $12,646 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,123 |
| Arnuity ElliptaFluticasone Furoate | 15 | $7,001 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $4,539 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $3,842 |
| Roflumilast | 36 | $1,213 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $1,195 |
| Azithromycin | 61 | $600 |
| Montelukast Sodium | 28 | $168 |
| Prednisone | 21 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $19 | $326,119444 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $50 | $43,69852 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $142 | $20,86942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Mequon
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
- Alfred HabelKenosha$194K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.